Lilly Will Tap Ambrx’s ReCODE Technology To Develop Metabolic, CNS Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership aims to yield first-in-class or best-in-class therapeutic antibodies and improved variants of native proteins, Ambrx tells “The Pink Sheet” DAILY.
You may also be interested in...
Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis
After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.
Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis
After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.
Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.